Opinion

Video

Addressing Unmet Needs in Synovial Sarcoma and Recent FDA Approval of Afami-cel

Panelists discuss how the major unmet needs in treating synovial sarcoma include developing targeted therapies that effectively address the SS18::SSX fusion oncogene, improving early detection methods, and finding ways to overcome treatment resistance in metastatic disease.

Video content above is prompted by the following:

  • What are the biggest unmet needs in treating synovial sarcoma today?

Related Videos
4 experts are featured in this series.
2 experts in this video
2 experts in this video
Related Content
R. Lor Randall, MD, FACS
December 23rd 2024

Osteosarcoma Spheroid Models Provide Key Tool for Preclinical Drug Development

Gina Z. D’Amato, MD
February 9th 2023

D'Amato Discusses Research and Resistance Mechanisms in Sarcoma and Gastrointestinal Stromal Tumor

FDA
November 25th 2024

FDA Approves Oral Solution of Imatinib for Certain Leukemias, Other Cancers

Somaiah Shares Insight on the Changing Landscapes of GIST, TGCT, and RAS/RAF-Mutant Tumors
December 29th 2022

Somaiah Shares Insight on the Changing Landscapes of GIST, TGCT, and RAS/RAF-Mutant Tumors

Pimicotinib in Tenosynovial Giant Cell Tumor | Image Credit: © 2rogan - stock.adobe.com
November 12th 2024

Pimicotinib Meets ORR End Point in Tenosynovial Giant Cell Tumor

Fixed-Dose CAR T Cells and UB-TT170 in R/R Osteosarcoma | Image Credit: © MdBabul - stock.adobe.com
November 11th 2024

Fixed-Dose CAR T Cells Followed by Escalating UB-TT170 Increases Cytokine Levels in R/R Osteosarcoma